Germany is a market that has great opportunities for healthcare companies. There are 82 million inhabitants living in a wealthy and aging society. The market in the hospital sector is comparably open and public health funds and private insurance companies have the ability to finance innovative projects and procedures.

Immunotherapies using oncolytic viruses - viruses that preferentially infect and kill cancer cells - offer a novel specific possibility of treating malignant tumors. Coxsackievirus B3 (CVB3) as an oncolytic RNA-virus possesses particular benefits including a short replication cycle, the generation of an abundant number of virus progeny, a strong cytolytic activity - cells bursting due to an osmotic imbalance -, and the introduction of robust anti-cancer immune responses.

The German company was founded in 1986 and is located in the Northeast of the country. As metalworking manufacturer the company owns a modern machinery park and is specialized in CNC turning, milling and lasering. Quality assurance is very important for the company. The company is quality certified by ISO 9001 and ISO 3834-2. In Germany, many tool manufacturer are on their limits of capacity. Therefore, the company is looking for a tool manufacturer in order to enhance their supplier portfolio. The toolmaker should be able to produce complex injection moulds out of steel.

Technological properties like shelf-life, compacting, hygroscopicity, electrostatic charging, solubility and many more can be improved by a deeper knowledge of solid-state chemistry and crystallography of products.